LOS ANGELES, April 04, 2017 -- Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against USANA Health Sciences, Inc. (“USANA” or the “Company”) (NYSE:USNA) concerning possible violations of federal securities laws between March 14, 2014 and February 7, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the April 14, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, USANA made materially false and/or misleading statements and/or failed to disclose that: the Company’s BabyCare Ltd. subsidiary engaged in improper reimbursement practices in China; that these practices constituted violations of the Foreign Corrupt Practices Act; that the Company’s China revenues were in part the product of unlawful conduct and unlikely to be sustainable; that the foregoing conduct was likely to subject the Company to significant regulatory scrutiny; and that as a result of the above, USANA’s public statements were materially false and misleading at all relevant times.
On February 7, 2017, USANA announced that “[t]he Company is voluntarily conducting an internal investigation of its China operations, BabyCare Ltd. The investigation focuses on compliance with the Foreign Corrupt Practices Act...and certain conduct and policies at BabyCare, including BabyCare’s expense reimbursement policies.” When this information was released to the public, shares of USANA fell in value, causing investors harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/


Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 



